Publications

Thai Court Rules Against Patent Infringement: Distributor Succeeds In Obtaining Rights To Trade Name

In the recent Thai case of Visit Taksapiboon v Modern Technique Lock Co., Ltd (Case No. 57/2007), the Central Intellectual Property and International Trade Court (CIPITC) considered a claim of patent infringement and a counter-claim against the Plaintiff for invalidation of the patent as well as a challenge against the Plaintiff's rights to use an […]

The on going battle against counterfeit anti-malaria drugs in South East Asia

In February this year, it was revealed that the International Criminal Police Organisation (INTERPOL) with the help of scientists and health workers from the World Health Organization (WHO) and Wellcome-Trust University of Oxford Tropical Medicine Research Programme, and the co-operation of Chinese authorities have uncovered a massive counterfeit anti- malaria drug syndicate, based in southern […]

A brief update on compulsory licensing and infectious diseases in ASEAN

Compulsory licensing has been a point of great dispute, with opinions torn between the rights of patent owners and accessibility to lifesaving, affordable drugs to the general public. The high cost of patent-protected pharmaceuticals and the inherent prevalence of infectious diseases such as HIV/AIDS, malaria and avian influenza are fueling demand for generic drugs and […]

The Military Government issues more compulsory licenses

On 25th January 2007, Thailand's military government stunned the pharmaceutical industry by their decision to issue more compulsory licenses with respect to drugs for treatment of heart diseases and AIDS. Earlier, in November last year, Thailand had issued its first compulsory license for making Efavirenz, an anti-retroviral drug manufactured by US pharmaceutical company Merck & […]

Thailand - Patients Before Patents

Thailand's military-backed Public Health Ministry has moved to assist the more than 500,000 people suffering from AIDS in the Kingdom by issuing its first compulsory license, directed at Efavirenz (brand names Sustiva® and Stocrin®). This decision, announced on Wednesday 27th November, was taken without any consultation with the patentee, Merck & Co. Inc, sparking a […]